Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride. - Test2 - elhamkhani - TriplyDB

Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride.

Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride.

http://www.wikidata.org/entity/Q34011162

about

The dopamine D1-D2 receptor heteromer localizes in dynorphin/enkephalin neurons: increased high affinity state following amphetamine and in schizophrenia Aripiprazole: from pharmacological profile to clinical use An intercalation mechanism as a mode of action exerted by psychotropic drugs: results of altered phospholipid substrate availabilities in membranes?Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future Effects of dopamine D2 receptor partial agonist antipsychotic aripiprazole on dopamine synthesis in human brain measured by PET with L-[β-11C]DOPA Reversible inhibitors of monoamine oxidase-A (RIMAs): robust, reversible inhibition of human brain MAO-A by CX157.Is the PANSS used correctly? a systematic review.Striatal and extrastriatal dopamine D2/D3 receptors in schizophrenia evaluated with [18F]fallypride positron emission tomography.Pathway-Specific Dopamine Abnormalities in Schizophrenia.Neuroimaging in psychiatric disorders Evaluation of dopamine D₂/₃ specific binding in the cerebellum for the positron emission tomography radiotracer [¹¹C]FLB 457: implications for measuring cortical dopamine release.Peripheral BDNF: a candidate biomarker of healthy neural activity during learning is disrupted in schizophrenia.18F-fallypride binding potential in patients with schizophrenia compared to healthy controls Relationship between dose, drug levels, and D2 receptor occupancy for the atypical antipsychotics risperidone and paliperidone.Predicting brain occupancy from plasma levels using PET: superiority of combining pharmacokinetics with pharmacodynamics while modeling the relationship Striatal D(2/3) Binding Potential Values in Drug-Naïve First-Episode Schizophrenia Patients Correlate With Treatment Outcome.Progress toward positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5).Placebo analgesia: Self-report measures and preliminary evidence of cortical dopamine release associated with placebo response.Establishing test-retest reliability of an adapted [(18)F]fallypride imaging protocol in older people.The hippocampus and nucleus accumbens as potential therapeutic targets for neurosurgical intervention in schizophrenia.Serotonin 2A receptors in obsessive-compulsive disorder: a positron emission tomography study with [11C]MDL 100907.Antipsychotic occupancy of dopamine receptors in schizophrenia.The use of PET imaging in studying cognition, genetics and pharmacotherapeutic interventions in schizophrenia.Presynaptic dopamine in schizophrenia.How have developments in molecular imaging techniques furthered schizophrenia research?Aripiprazole: a review of its use in the management of mania in adults with bipolar I disorder.Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism.Therapeutic D2/3 receptor occupancies and response with low amisulpride blood concentrations in very late-onset schizophrenia-like psychosis (VLOSLP).Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease.Cognitive Impairment in Schizophrenia, Neurotransmitters and the New Atypical Antipsychotic Aripiprazole.A Case of Aripiprazole-Induced Tardive Dyskinesia with Dramatic Evolution.In vivo imaging of brain microglial activity in antipsychotic-free and medicated schizophrenia: a [(11)C](R)-PK11195 positron emission tomography study.Model-based approaches to increase efficiency of drug development in schizophrenia: a can't miss opportunity.The Harms of Antipsychotic Drugs: Evidence from Key Studies.In vivo binding of antipsychotics to D3 and D2 receptors: a PET study in baboons with [11C]-(+)-PHNO.Not all partial dopamine D(2) receptor agonists are the same in treating schizophrenia. Exploring the effects of bifeprunox and aripiprazole using a computer model of a primate striatal dopaminergic synapse.Characterization of in vivo pharmacokinetic properties of the dopamine D1 receptor agonist DAR-0100A in nonhuman primates using PET with [11C] NNC112 and [11C] raclopride.The relationship between antipsychotic D2 occupancy and change in frontal metabolism and working memory : A dual [(11)C]raclopride and [(18) F]FDG imaging study with aripiprazole.Striatal and extrastriatal dopamine D₂ receptor occupancy by the partial agonist antipsychotic drug aripiprazole in the human brain: a positron emission tomography study with [¹¹C]raclopride and [¹¹C]FLB457.

P2860

Q24608243-F1D3C196-72CE-48E0-8970-7158374639A5 Q26778312-9D93E5DB-0628-48E2-8BCA-A44E9AF76009 Q27491346-B97F7BF7-0879-4BD5-AEAC-3B714C720EB0 Q28084069-06A8BD39-7FBD-4D6D-B8B3-8126E5F1CCA3 Q28394341-36A6AAF6-E14E-49DE-B808-347317D8149B Q28484113-AD47D7F2-1D2B-479D-8F9F-0499F8F3F330 Q33708210-92BDC94C-733E-48B9-B336-18E240081D8C Q33964357-341B0CF3-70EA-474E-98E7-B3BE44A8FF90 Q34187457-7E390789-E27A-4550-A69C-6D6E68CEF62C Q34527656-49749A92-3A84-46D6-BE47-C5A2DB86D716 Q34644697-DA21E2BA-5B88-4454-BC41-E2FD19E0D239 Q35103315-4E9092C1-A337-4BA5-BE01-B80D7D6CD6B3 Q35550864-BC0F5A24-A652-4B26-BCB1-FA45DC51EE41 Q35752862-7D8C4485-13BB-4026-8DBD-EEBE7042DBC6 Q35847706-A886C4FD-CE75-4CDC-B538-A4BC5B644FDA Q35866868-B4118E93-74BE-40FA-A2AD-96880FA4C344 Q35950793-E1F9C10F-365E-4B9D-BB4C-7F3BDB9110AA Q36015452-B183DDDF-97F8-4A03-987E-E1233AADD5C9 Q36382450-CDDCEB46-DDBD-4784-B6AA-F17E87F98FF8 Q36994341-E457AE17-2299-415E-8C76-22AA91B870A0 Q37531716-227D1710-6AE0-4F63-A3C9-BEC60D52B511 Q37633750-F5DA91CF-1F33-44CA-87BF-833E78220910 Q37818511-80E1B1A8-987C-4288-95B8-6058612E447A Q37820985-1DC0F2E5-26F3-4412-8143-6CD83714A718 Q37825635-C9B734BE-59B5-4F74-B1C5-F75EEAF282C7 Q37829639-AB46335B-8E42-4D81-93CE-CE901E08D49F Q37970762-8742917F-28E2-4DD4-9FD5-3B8C0CD4B4C6 Q37983747-CE0F6447-5BEB-4632-A797-0C6463EF12FA Q38667647-28EC2DE8-9FF4-47D3-BBD0-F6F5EA344125 Q38740848-8B32BB02-61AE-4738-A017-E319C82B37BD Q38844790-2BC35F7C-7FE1-4666-B440-E414C0EBBED5 Q39210357-7F47B799-99AD-4946-8D79-D1636D842655 Q39326557-AC861EA5-8E09-4E65-A289-FAD99B0EA5ED Q39959170-BEF29030-7AB3-47AB-B0EB-9A22FB9F6E32 Q40467111-7ADCF294-1E7D-4479-9E78-4024522FE380 Q41909369-D3AD91AE-4640-46EE-9B72-7A9A2043FE9F Q41918764-66A9601A-22CD-4F62-B91D-0C92050A32F4 Q42652786-062890CE-2754-456F-850A-25718B287AA9 Q43922950-14940DFD-2312-48E2-B391-38F64748CA6F Q44009699-954C1F1B-D482-4E78-A79C-F245C0CDD8A2

P2860

Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride.

http://www.wikidata.org/entity/Q34011162

description

2008 nî lūn-bûn

@nan

2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Dose-occupancy study of striat ...... with PET and [18F]fallypride.

@ast

Dose-occupancy study of striat ...... with PET and [18F]fallypride.

@en

Dose-occupancy study of striat ...... with PET and [18F]fallypride.

@nl

type

label

Dose-occupancy study of striat ...... with PET and [18F]fallypride.

@ast

Dose-occupancy study of striat ...... with PET and [18F]fallypride.

@en

Dose-occupancy study of striat ...... with PET and [18F]fallypride.

@nl

prefLabel

Dose-occupancy study of striat ...... with PET and [18F]fallypride.

@ast

Dose-occupancy study of striat ...... with PET and [18F]fallypride.

@en

Dose-occupancy study of striat ...... with PET and [18F]fallypride.

@nl

P1433

Q34011162-2821D2BD-56F6-4F3A-9C08-40EF6EB0A248

P1476

Q34011162-28ACCD7D-5B35-4B9D-B7FB-D45EB6DC3740

P2093

Q34011162-059AA880-0A1E-4C2D-AB39-0F8176B9650F

Q34011162-1319E8B5-E778-4D10-ACAA-DA6198EFE8EC

Q34011162-1A9BA598-F087-4221-896E-780A5ADB2998

Q34011162-2787497E-DE9E-4D38-8F40-DA6E0CEE21A5

Q34011162-387D8FD2-A3E7-4838-9E8B-4DA52311B4A1

Q34011162-3D9D46D9-04C4-453C-B7EC-8901951023B7

Q34011162-5B39D2EE-3A9B-4B42-BC32-76B32EDA20D9

Q34011162-7D93750D-95AB-40AF-8FD4-F749E0700764

Q34011162-89F18F70-8A48-4462-B75B-88357106E0DD

Q34011162-B02FF703-F028-4435-B9D8-1B9B4C39EC8D

P2860

Q34011162-0AA75C3A-02FD-4584-A991-573DDA82F620

Q34011162-0CAA1373-0074-42A3-A03A-54BEEE4BCD54

Q34011162-149FE76B-78DC-40CD-B6D9-4657E0E4E827

Q34011162-2311D6CD-95FD-4249-AF98-20D983C7C551

Q34011162-25AD7C70-D1C9-4A32-90E2-2D2D614756F9

Q34011162-28906A85-5430-45CE-A91F-A7F96B1CED10

Q34011162-41407062-83F1-48B4-B548-5A41E3D49585

Q34011162-47AB3039-952A-4B45-903B-785B00E9AE29

Q34011162-4C4247C5-68C8-4FCA-9E16-6E5D60B2ACC5

Q34011162-4C4C03A5-5D3F-4C18-878B-D34852306036

P2888

Q34011162-255836A5-6216-4A4D-A394-C06AD1A1A1EC

P304

Q34011162-6E52F10C-8996-42FC-BB03-85E25B227199

P31

Q34011162-61747822-9640-47FE-BC5D-67254DF7E7A9

P356

Q34011162-BA67CFAF-0379-4A9E-8422-459BED72F1C4

P407

Q34011162-2474002E-CA46-425E-B95B-EC1EF07B586B

P433

Q34011162-D33A191C-6B4C-43EC-8FB8-C9277161786D

P478

Q34011162-8F59105B-E33A-4D21-967B-EB4032C746FC

P50

Q34011162-D480297C-251B-4663-AA14-49E2316958A8

P577

Q34011162-4820ED79-41C2-461E-82CF-E7E32DB1A8FB

P5875

Q34011162-953BF45D-2427-40B7-8507-B1195DC82C05

P6179

Q34011162-6E9F072E-A35C-4954-9139-2A0FCAB0F388

Q34011162-AC6268F4-58C7-4CCC-B2EE-D0EFDAB7BA5B

P698

Q34011162-4D55D36E-CB21-42FA-9A8B-C7852E6A6EB2

P921

Q34011162-351BA71E-140B-409A-BF32-41E43879F69F

Q34011162-662F31C8-B888-4112-AE5E-2AFFFD988786

Q34011162-9282e598-daa9-4d2a-8a99-0d56a973f23f

P356

P1433

Neuropsychopharmacology

P1476

Dose-occupancy study of striat ...... with PET and [18F]fallypride.

@en

P2093

Beatriz Alvarez

http://www.w3.org/2001/XMLSchema#string

Elizabeth Hackett

http://www.w3.org/2001/XMLSchema#string

Jong-Hoon Kim

http://www.w3.org/2001/XMLSchema#string

Lawrence S Kegeles

http://www.w3.org/2001/XMLSchema#string

Marc Laruelle

http://www.w3.org/2001/XMLSchema#string

Mark Slifstein

http://www.w3.org/2001/XMLSchema#string

Roberto Gil

http://www.w3.org/2001/XMLSchema#string

Robyn Gonzales

http://www.w3.org/2001/XMLSchema#string

Sung-A Bae

http://www.w3.org/2001/XMLSchema#string

W Gordon Frankle

http://www.w3.org/2001/XMLSchema#string

P2860

Functional Selectivity and Classical Concepts of Quantitative Pharmacology

Increased baseline occupancy of D2 receptors by dopamine in schizophrenia

Statistical parametric maps in functional imaging: A general linear approach

The positive and negative syndrome scale (PANSS) for schizophrenia

Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects

Potentials and pitfalls using high affinity radioligands in PET and SPET determinations on regional drug induced D2 receptor occupancy--a simulation study based on experimental data.

Fluorinated benzamide neuroleptics--III. Development of (S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3-[18F]fluoropropyl)-2, 3-dimethoxybenzamide as an improved dopamine D-2 receptor tracer.

Agonist-receptor efficacy. II. Agonist trafficking of receptor signals.

Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia.

Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers.

P2888

P304

3111-3125

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NPP.2008.33

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P50

Anissa Abi-Dargham

P577

2008-04-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5435026

http://www.w3.org/2001/XMLSchema#string

P6179

1011713834

http://www.w3.org/2001/XMLSchema#string

P698

18418366

http://www.w3.org/2001/XMLSchema#string

P921

corpus striatum